Differences underlying EGFR and HER2 oncogene addiction.
作者信息
Faber Anthony C, Wong Kwok-Kin, Engelman Jeffrey A
出版信息
Cell Cycle. 2010 Mar 1;9(5):851-2. doi: 10.4161/cc.9.5.11096. Epub 2010 Mar 30.
Abstract
摘要
相似文献
1
Differences underlying EGFR and HER2 oncogene addiction.表皮生长因子受体（EGFR）和人表皮生长因子受体2（HER2）致癌基因成瘾的潜在差异。
Cell Cycle. 2010 Mar 1;9(5):851-2. doi: 10.4161/cc.9.5.11096. Epub 2010 Mar 30.
2
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.一种神经调节蛋白-表皮生长因子受体（EGFR）-人表皮生长因子受体3（HER3）自分泌信号轴可介导HER2阳性乳腺癌模型中对拉帕替尼的获得性耐药。
Breast Cancer Res. 2013;15(5):R85. doi: 10.1186/bcr3480.
3
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.BIM 在初治癌症中的表达可预测对激酶抑制剂的反应性。
Cancer Discov. 2011 Sep;1(4):352-65. doi: 10.1158/2159-8290.CD-11-0106. Epub 2011 Jul 22.
4
Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways.飞燕草素通过靶向 EGFR/VEGFR2 信号通路减少非小细胞肺癌细胞的增殖并诱导其凋亡。
PLoS One. 2013 Oct 4;8(10):e77270. doi: 10.1371/journal.pone.0077270. eCollection 2013.
5
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.间充质样非小细胞肺癌细胞系中的激酶转换通过信号通路冗余导致表皮生长因子受体（EGFR）抑制剂耐药。
Clin Exp Metastasis. 2008;25(8):843-54. doi: 10.1007/s10585-008-9200-4. Epub 2008 Aug 12.
6
Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification.在MET 扩增的肺癌中，跨磷酸化的 EGFR、HER2、HER3 和 RET 作为 MET 异二聚体化伙伴的不同作用。
Br J Cancer. 2011 Sep 6;105(6):807-13. doi: 10.1038/bjc.2011.322. Epub 2011 Aug 16.
7
Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.携带有 HER2 上 T798M 看门突变的人乳腺癌细胞过度表达 EGFR 配体，并对 EGFR 和 HER2 的双重抑制敏感。
Clin Cancer Res. 2013 Oct 1;19(19):5390-401. doi: 10.1158/1078-0432.CCR-13-1038. Epub 2013 Aug 15.
8
A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion.人头颈癌细胞中 HER2 和 ADAM12 之间的正反馈环可增强迁移和侵袭能力。
Oncogene. 2012 Jun 7;31(23):2888-98. doi: 10.1038/onc.2011.460. Epub 2011 Oct 10.
9
HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.HER2阳性癌细胞对PI3K与MAPK信号轴的依赖性由EGFR、ERBB3和CDKN1B的表达决定。
PLoS Comput Biol. 2016 Apr 1;12(4):e1004827. doi: 10.1371/journal.pcbi.1004827. eCollection 2016 Apr.
10
PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations.PCC0208027，一种新型的酪氨酸激酶抑制剂，通过靶向 EGFR 和 HER2 异常抑制 NSCLC 的肿瘤生长。
Sci Rep. 2019 Apr 5;9(1):5692. doi: 10.1038/s41598-019-42245-3.
引用本文的文献
1
DARPin_9-29-Targeted Gold Nanorods Selectively Suppress HER2-Positive Tumor Growth in Mice.靶向 DARPin_9-29 的金纳米棒可选择性抑制小鼠体内 HER2 阳性肿瘤的生长。
Cancers (Basel). 2021 Oct 19;13(20):5235. doi: 10.3390/cancers13205235.
2
Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.MEK 抑制通过独立的 MYC 和 BIM 调控抑制肝细胞癌生长。
Cell Oncol (Dordr). 2019 Jun;42(3):369-380. doi: 10.1007/s13402-019-00432-4. Epub 2019 Feb 20.
3
ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.表皮生长因子受体（ErbB）家族信号传导：癌基因成瘾与个性化肿瘤学的范例
Cancers (Basel). 2017 Apr 12;9(4):33. doi: 10.3390/cancers9040033.
4
Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.抑制IGF1R信号传导可消除EGFR T790M突变肺癌细胞对阿法替尼（BIBW2992）的耐药性。
Mol Carcinog. 2016 May;55(5):991-1001. doi: 10.1002/mc.22342. Epub 2015 Jun 4.
5
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics.BCL2家族：靶向抗癌治疗凋亡反应的关键调节因子
Cancer Discov. 2015 May;5(5):475-87. doi: 10.1158/2159-8290.CD-15-0011. Epub 2015 Apr 20.
6
A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells.一种具有抗肿瘤活性的苯并咪唑衍生物可阻断乳腺癌细胞中的表皮生长因子受体（EGFR）和人表皮生长因子受体2（HER2）活性，并上调死亡受体5（DR5）。
Cell Death Dis. 2015 Mar 12;6(3):e1686. doi: 10.1038/cddis.2015.25.
7
Identification of drivers from cancer genome diversity in hepatocellular carcinoma.从肝细胞癌的癌症基因组多样性中识别驱动因素。
Int J Mol Sci. 2014 Jun 20;15(6):11142-60. doi: 10.3390/ijms150611142.
8
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.表皮生长因子受体家族：从癌基因发现到基础科学再到基于机制的癌症治疗。
Cancer Cell. 2014 Mar 17;25(3):282-303. doi: 10.1016/j.ccr.2014.02.025.
9
Prognostic importance and therapeutic implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma.PAK1 在胃食管结合部腺癌中的预后意义及药物治疗靶点的相关影响。
PLoS One. 2013 Nov 13;8(11):e80665. doi: 10.1371/journal.pone.0080665. eCollection 2013.
10
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer.基于曲妥珠单抗治疗HER2过表达乳腺癌的分子机制
ISRN Oncol. 2012;2012:428062. doi: 10.5402/2012/428062. Epub 2012 Nov 22.
本文引用的文献
1
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.PI3K抑制后HER2和EGFR依赖型癌症中凋亡的差异诱导
Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19503-8. doi: 10.1073/pnas.0905056106. Epub 2009 Oct 22.
2
Targeting PI3K signalling in cancer: opportunities, challenges and limitations.靶向癌症中的PI3K信号通路：机遇、挑战与局限
Nat Rev Cancer. 2009 Aug;9(8):550-62. doi: 10.1038/nrc2664.
3
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.NVP-BEZ235，一种双PI3K/mTOR抑制剂，可阻止PI3K信号传导并抑制具有激活PI3K突变的癌细胞的生长。
Cancer Res. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385.
4
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.具有PI3K突变或HER2扩增的乳腺肿瘤细胞对Akt信号传导存在选择性依赖。
PLoS One. 2008 Aug 26;3(8):e3065. doi: 10.1371/journal.pone.0003065.
5
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.非小细胞肺癌中对表皮生长因子受体酪氨酸激酶抑制剂获得性耐药的机制
Clin Cancer Res. 2008 May 15;14(10):2895-9. doi: 10.1158/1078-0432.CCR-07-2248.
6
Acquired resistance to tyrosine kinase inhibitors during cancer therapy.癌症治疗期间对酪氨酸激酶抑制剂产生的获得性耐药。
Curr Opin Genet Dev. 2008 Feb;18(1):73-9. doi: 10.1016/j.gde.2008.01.004. Epub 2008 Mar 5.
7
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.MET扩增通过激活ERBB3信号通路导致肺癌对吉非替尼耐药。
Science. 2007 May 18;316(5827):1039-43. doi: 10.1126/science.1141478. Epub 2007 Apr 26.
8
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.由死亡信号引发的线粒体决定细胞对抗凋亡BCL-2家族成员的依赖性。
Cancer Cell. 2006 May;9(5):351-65. doi: 10.1016/j.ccr.2006.03.027.
9
Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function.Erk1/2在丝氨酸69位点对Bim-EL的磷酸化作用通过蛋白酶体途径促进其降解，并调节其促凋亡功能。
Oncogene. 2003 Oct 2;22(43):6785-93. doi: 10.1038/sj.onc.1206792.
Zotero 插件